<table border="single" id="id_d1d5a1a6-5d6d-4530-b7b5-5e7233ecd874" width="567" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_9422a292-c737-4afa-9ce7-4981922f06b4"> Table 12: Results of Drug Interaction Studies with Buffered Formulations of Didanosine:                  Effects of Didanosine on Coadministered Drug Plasma AUC and C<sub>max</sub> Values</caption>
<col width="30.2%"></col>
<col width="17.1%"></col>
<col width="9.3%"></col>
<col width="19.9%"></col>
<col width="23.5%"></col>
<tfoot id="id_a8551d95-4415-41c9-8915-01625dc84803">
<tr>
<td align="left" colspan="5" stylecode="Botrule" valign="top">  ↑  Indicates increase.<br/>↓  Indicates decrease.<br/>↔ Indicates no change, or mean increase or decrease of less than 10%.<br/>NA = Not available.</td>
</tr>
</tfoot>
<tbody>
<tr id="id_7254005a-a158-4aa4-8a23-47818b664b85">
<td align="left" colspan="3" stylecode="Toprule" valign="top"></td>
<td align="left" colspan="2" stylecode="Botrule" valign="top">
<content stylecode="bold">% Change of Coadministered Drug Pharmacokinetic Parameters<footnote id="id-f01ed53a-8aae-4803-8618-9466d98f11a2">The 95% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.</footnote>
</content>
</td>
</tr>
<tr id="id_bd821aa8-4a9f-4e79-adfb-82cea95e46c4">
<td align="center" colspan="3" stylecode="Botrule" valign="top">
<paragraph>            </paragraph>
<content stylecode="bold">              Drug                                Didanosine Dosage                       n        </content>
</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>
<content stylecode="bold">AUC of Coadministered Drug</content>
</paragraph>
<content stylecode="bold">(95% CI)</content>
</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>
<content stylecode="bold">C<sub>max</sub> of Coadministered Drug</content>
</paragraph>
<content stylecode="bold">(95% CI)</content>
</td>
</tr>
<tr id="id_a9e81ec8-ce58-4309-8bfe-b0f6cd7f846e">
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>dapsone, 100 mg single dose</paragraph>
<paragraph>ganciclovir, 1000 mg every 8 hours, 2 hours after didanosine</paragraph>
<paragraph>nelfinavir, 750 mg single dose, 1 hour after didanosine</paragraph>
<paragraph>ranitidine, 150 mg single dose, 2 hours before didanosine</paragraph>
<paragraph>ritonavir, 600 mg every 12 hours for 4 days</paragraph>
<paragraph>stavudine, 40 mg every 12 hours for 4 days</paragraph>
<paragraph>sulfamethoxazole, 1000 mg single dose</paragraph>
<paragraph>trimethoprim, 200 mg single dose</paragraph>
zidovudine, 200 mg every 8 hours for 3 days</td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>200 mg every 12 hours</paragraph>
<paragraph>for 14 days</paragraph>
<paragraph>200 mg every 12 hours</paragraph>
<paragraph>200 mg single dose</paragraph>
<paragraph>375 mg single dose</paragraph>
<paragraph>200 mg every 12 hours</paragraph>
<paragraph>for 4 days</paragraph>
<paragraph>100 mg every 12 hours</paragraph>
<paragraph>for 4 days</paragraph>
<paragraph>200 mg single dose</paragraph>
<paragraph>200 mg single dose</paragraph>
<paragraph>200 mg every 12 hours</paragraph>
for 3 days</td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>6<footnote id="id-4c27a32b-08cf-4757-b647-2b1053b61f76">HIV-infected patients.</footnote>
</paragraph>
<paragraph>12<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</paragraph>
<paragraph>10<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</paragraph>
<paragraph>12<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</paragraph>
<paragraph>12</paragraph>
<paragraph>10<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</paragraph>
<paragraph>8<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</paragraph>
<paragraph>8<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</paragraph>
6<footnoteref idref="id-4c27a32b-08cf-4757-b647-2b1053b61f76"></footnoteref>
</td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>↔</paragraph>
<paragraph>↓ 21%</paragraph>
<paragraph>↑ 12%</paragraph>
<paragraph>↓ 16%</paragraph>
<paragraph>↔</paragraph>
<paragraph>↔</paragraph>
<paragraph>↓ 11%</paragraph>
<paragraph>(-17, -4%)</paragraph>
<paragraph>↑ 10%</paragraph>
<paragraph>(-9, 34%)</paragraph>
<paragraph>↓ 10%</paragraph>
(-27, 11%)</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>↔</paragraph>
<paragraph>NA</paragraph>
<paragraph>↔</paragraph>
<paragraph>↔</paragraph>
<paragraph>↔</paragraph>
<paragraph>↑ 17%</paragraph>
<paragraph>↓ 12%</paragraph>
<paragraph>(-28, 8%)</paragraph>
<paragraph>↓ 22%</paragraph>
<paragraph>(-59, 49%)</paragraph>
<paragraph>↓ 16.5%</paragraph>
(-53, 47%)</td>
</tr>
</tbody>
</table>